Veoza Approved for Menopause Treatment
Veoza (fezolinetant) has been officially approved for use on the NHS in England, providing a new treatment option for menopausal women suffering from hot flushes. This decision is expected to benefit around 500,000 women who experience these symptoms, which affect approximately 70% of women undergoing menopause.
The approval of Veoza is particularly significant for women for whom hormone replacement therapy (HRT) is unsuitable. Helen Knight, a representative from NICE, stated, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” This sentiment underscores the importance of offering alternatives to HRT.
Veoza is designed as a once-daily oral tablet that works by blocking nerve pathways in the brain responsible for triggering hot flushes and night sweats. The NHS has set the list price for Veoza at £44.80 for a 28-tablet pack, a cost that NICE has deemed to be cost-effective and valuable for taxpayers.
Dr. Sue Mann, a menopause specialist, welcomed the approval, noting, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” This highlights the need for effective treatments that cater to diverse patient needs.
Historically, treatment options for menopausal hot flushes have been limited, with few safe and effective alternatives available for decades. The introduction of Veoza marks a significant advancement in addressing this widespread issue, offering hope to many women seeking relief from debilitating symptoms.
As the healthcare community begins to integrate Veoza into treatment plans, observers anticipate that it will provide much-needed relief for those affected by menopause. Dr. Mann added, “It’s another vital treatment option which could help hundreds of thousands of women experiencing menopause to better manage their symptoms and feel more in control of their health.”
While the approval is a positive step forward, details remain unconfirmed regarding the long-term effects and overall patient satisfaction with Veoza. Continued monitoring and research will be essential to ensure that this new treatment meets the needs of women experiencing menopause.